Choksi Laboratories Ltd Valuation Shift Signals Renewed Price Attractiveness

Valuation Metrics and Recent Changes

As of 10 Sep 2026, Choksi Laboratories trades at ₹173.35, up 5.00% from the previous close of ₹165.10. The stock’s 52-week range spans from ₹81.85 to ₹229.45, indicating significant volatility over the past year. The company’s price-to-earnings (P/E) ratio currently stands at 63.49, a figure that, while high, has contributed to its valuation grade improving from very attractive to attractive. This suggests that despite the elevated P/E, investors are beginning to price in growth prospects or quality improvements.

Price-to-book value (P/BV) is at 4.72, which remains elevated but consistent with the sector’s premium valuations. Other enterprise value multiples include EV/EBIT at 29.56 and EV/EBITDA at 12.11, both reflecting a relatively expensive stance compared to some peers but more reasonable than others in the healthcare services space.

Comparative Peer Analysis

When compared with peers, Choksi Laboratories’ valuation metrics present a mixed picture. For instance, KMC Speciality, another healthcare services firm, trades at a P/E of 40.41 but is considered expensive due to a higher EV/EBITDA of 22.84. Suraksha Diagnostics, with a P/E of 48.89 and EV/EBITDA of 18.17, is rated fair. On the other hand, Gujarat Kidney and Gaudium IVF are classified as very expensive, with P/E ratios of 86.91 and 37.04 respectively, and EV/EBITDA multiples well above 20.

Interestingly, Asarfi Hospital is rated very attractive with a P/E of 22.31 and EV/EBITDA of 12.28, indicating that Choksi Laboratories’ current valuation is somewhat stretched relative to the most attractively priced peers but more reasonable than the very expensive ones.

Financial Performance and Returns

Choksi Laboratories’ return metrics over various periods reveal a strong long-term performance despite recent setbacks. The stock has delivered a remarkable 844.69% return over five years and 201.74% over three years, vastly outperforming the Sensex’s 28.23% and 12.26% respectively. Year-to-date, the stock is up 34.17%, while the Sensex has declined 12.27%. However, the one-year return is negative at -23.11%, underperforming the Sensex’s -7.81%, signalling some recent headwinds or profit-taking.

Return on capital employed (ROCE) and return on equity (ROE) stand at 8.95% and 7.43% respectively, indicating moderate profitability but room for improvement compared to sector averages. The PEG ratio of 2.38 suggests that the stock’s price is factoring in growth, though at a premium relative to some peers with lower PEGs.

Market Capitalisation and Mojo Score Implications

Choksi Laboratories is classified as a micro-cap stock, which inherently carries higher volatility and risk compared to larger peers. Its Mojo Score currently stands at 44.0, with a Mojo Grade downgraded from Hold to Sell as of 09 Sep 2026. This downgrade reflects concerns about valuation sustainability and possibly the company’s operational or financial outlook.

The downgrade signals caution for investors, especially given the stretched P/E ratio and moderate profitability metrics. The market’s recent enthusiasm, as evidenced by a 5% day gain and strong short-term returns, may be tempered by these fundamental considerations.

Valuation Grade Shift: From Very Attractive to Attractive

The shift in valuation grade from very attractive to attractive is significant. It indicates that while the stock remains appealing relative to some peers and historical levels, the margin of safety has narrowed. Investors who previously viewed the stock as undervalued may now see it as fairly valued or slightly expensive, necessitating a more cautious approach.

This change is likely driven by the stock’s price appreciation, which has outpaced earnings growth, pushing the P/E ratio higher. Additionally, the P/BV multiple of 4.72, though not extreme in the healthcare sector, suggests that the market is pricing in premium growth or quality factors.

Sector and Market Context

The healthcare services sector often commands premium valuations due to its growth potential and defensive characteristics. However, Choksi Laboratories’ valuation multiples, particularly EV/EBITDA at 12.11, are moderate compared to some peers with multiples exceeding 20 or even 50. This relative moderation may appeal to investors seeking exposure to healthcare with less valuation risk.

Comparing the stock’s returns to the Sensex highlights its strong long-term outperformance, though recent underperformance over one year suggests some cyclical or company-specific challenges. Investors should weigh these factors carefully when considering entry or exit points.

Investor Takeaways and Outlook

For investors, the evolving valuation landscape of Choksi Laboratories Ltd suggests a need for prudence. The stock’s attractive rating indicates it is not overvalued relative to its sector and peers, but the upward shift in multiples warrants careful monitoring of earnings growth and profitability improvements.

Given the micro-cap status and recent Mojo Grade downgrade to Sell, risk-averse investors may prefer to wait for clearer signs of operational momentum or valuation stabilisation before committing fresh capital. Conversely, those with a higher risk tolerance might view the current price as a reasonable entry point, supported by strong long-term returns and sector tailwinds.

Ultimately, the stock’s future attractiveness will hinge on its ability to sustain earnings growth, improve return ratios, and justify its premium multiples in a competitive healthcare services environment.

Summary

Choksi Laboratories Ltd’s valuation parameters have shifted, reflecting a transition from very attractive to attractive status. While the stock remains compelling relative to many peers, elevated P/E and P/BV ratios alongside a recent Mojo Grade downgrade highlight emerging risks. Long-term returns have been impressive, but recent volatility and profitability metrics suggest investors should balance optimism with caution. The healthcare services sector’s growth prospects provide a supportive backdrop, yet micro-cap risks and valuation pressures remain key considerations.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →